0 317

Cited 9 times in

A new prognostic model using absolute lymphocyte count in patients with primary central nervous system lymphoma

DC FieldValueLanguage
dc.contributor.author김수정-
dc.contributor.author민유홍-
dc.contributor.author박현성-
dc.contributor.author이정연-
dc.contributor.author장지은-
dc.contributor.author정준원-
dc.contributor.author정해림-
dc.contributor.author김유리-
dc.contributor.author김윤덕-
dc.contributor.author김진석-
dc.date.accessioned2017-02-24T11:22:56Z-
dc.date.available2017-02-24T11:22:56Z-
dc.date.issued2016-
dc.identifier.issn0959-8049-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/146753-
dc.description.abstractPURPOSE: Primary central nervous system lymphoma (PCNSL) is an aggressive and rare extranodal non-Hodgkin lymphoma (NHL). Absolute lymphocyte count (ALC) has been suggested to have a prognostic value in several subtypes of NHL. We evaluated the prognostic significance of clinical factors, including ALC, in patients with PCNSL to develop a new prognostic model. METHODS: We analysed prognostic factors, including ALC, at diagnosis in 81 PCNSL patients receiving high-dose methotrexate-based therapy. RESULTS: The median ALC at diagnosis was 1210 × 10(6)/L (range, 210-3610), with lymphopenia (≤ 875 × 10(6)/L) being detected in 27 (33.3%) patients. In the multivariate analysis, Eastern Cooperative Oncology Group performance status (ECOG PS) >1 (hazard ratio [HR] 3.18, P=0.003), age >50 years (HR 4.23, P=0.012), and lymphopenia at diagnosis (HR 2.83, P=0.008) remained independent prognostic factors for low overall survival (OS). Lymphopenia was also a significant prognostic factor for progression-free survival (HR 3.17, P=0.001). By means of a new three-factor prognostic model using ECOG PS >1, age >50 years, and presence of lymphopenia, with 1 point assigned to each factor, we successfully classified the patients into three risk groups: low (0 and 1), intermediate (2), and high (3). The 5-year OS rates of the patients in the low-, intermediate-, and high-risk groups were 74.3%, 21.7%, and 12.5%, respectively (P<0.001). CONCLUSIONS: Low ALC is a useful indicator of poor prognosis in patients with PCNSL. The proposed three-factor model should be validated in large-scale studies.-
dc.description.statementOfResponsibilityrestriction-
dc.format.extent127~135-
dc.languageEnglish-
dc.publisherElsevier Science Ltd-
dc.relation.isPartOfEUROPEAN JOURNAL OF CANCER-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols/therapeutic use-
dc.subject.MESHBusulfan/administration & dosage-
dc.subject.MESHCentral Nervous System Neoplasms/diagnosis-
dc.subject.MESHCentral Nervous System Neoplasms/mortality*-
dc.subject.MESHCentral Nervous System Neoplasms/therapy-
dc.subject.MESHCombined Modality Therapy-
dc.subject.MESHDexamethasone/administration & dosage-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHKaplan-Meier Estimate-
dc.subject.MESHLymphocyte Count/methods-
dc.subject.MESHLymphoma, Non-Hodgkin/diagnosis-
dc.subject.MESHLymphoma, Non-Hodgkin/mortality*-
dc.subject.MESHLymphoma, Non-Hodgkin/therapy-
dc.subject.MESHLymphopenia/etiology-
dc.subject.MESHLymphopenia/mortality*-
dc.subject.MESHMale-
dc.subject.MESHMethotrexate/administration & dosage-
dc.subject.MESHMiddle Aged-
dc.subject.MESHPrognosis-
dc.subject.MESHStem Cell Transplantation-
dc.subject.MESHThiotepa/administration & dosage-
dc.subject.MESHTransplantation, Autologous-
dc.subject.MESHVincristine/administration & dosage-
dc.titleA new prognostic model using absolute lymphocyte count in patients with primary central nervous system lymphoma-
dc.typeArticle-
dc.publisher.locationEngland-
dc.contributor.collegeCollege of Medicine-
dc.contributor.departmentDept. of Internal Medicine-
dc.contributor.googleauthorJi Eun Jang-
dc.contributor.googleauthorYu Ri Kim-
dc.contributor.googleauthorSoo-Jeong Kim-
dc.contributor.googleauthorHyunsoo Cho-
dc.contributor.googleauthorHaerim Chung-
dc.contributor.googleauthorJung Yeon Lee-
dc.contributor.googleauthorHyunsung Park-
dc.contributor.googleauthorYundeok Kim-
dc.contributor.googleauthorJune-Won Cheong-
dc.contributor.googleauthorYoo Hong Min-
dc.contributor.googleauthorJin Seok Kim-
dc.identifier.doi10.1016/j.ejca.2016.01.016-
dc.contributor.localIdA00633-
dc.contributor.localIdA01407-
dc.contributor.localIdA01740-
dc.contributor.localIdA03114-
dc.contributor.localIdA03477-
dc.contributor.localIdA03729-
dc.contributor.localIdA04674-
dc.contributor.localIdA00779-
dc.contributor.localIdA00790-
dc.contributor.localIdA01017-
dc.relation.journalcodeJ00809-
dc.identifier.eissn1879-0852-
dc.identifier.pmid26918738-
dc.identifier.urlhttp://www.sciencedirect.com/science/article/pii/S095980491600054X-
dc.subject.keywordLymphopenia-
dc.subject.keywordPrimary central nervous system lymphoma-
dc.subject.keywordPrognosis-
dc.contributor.alternativeNameKim, Soo Jeong-
dc.contributor.alternativeNameMin, Yoo Hong-
dc.contributor.alternativeNamePark, Hyeun Sung-
dc.contributor.alternativeNameLee, Jung Yoen-
dc.contributor.alternativeNameJang, Ji Eun-
dc.contributor.alternativeNameCheong, June Won-
dc.contributor.alternativeNameChung, Hae Rim-
dc.contributor.alternativeNameKim, Yu Ri-
dc.contributor.alternativeNameKim, Yun Deok-
dc.contributor.alternativeNameKim, Jin Seok-
dc.contributor.affiliatedAuthorKim, Soo Jeong-
dc.contributor.affiliatedAuthorMin, Yoo Hong-
dc.contributor.affiliatedAuthorPark, Hyeun Sung-
dc.contributor.affiliatedAuthorLee, Jung Yoen-
dc.contributor.affiliatedAuthorJang, Ji Eun-
dc.contributor.affiliatedAuthorCheong, June-Won-
dc.contributor.affiliatedAuthorChung, Hae Rim-
dc.contributor.affiliatedAuthorKim, Yu Ri-
dc.contributor.affiliatedAuthorKim, Yun Deok-
dc.contributor.affiliatedAuthorKim, Jin Seok-
dc.citation.volume57-
dc.citation.startPage127-
dc.citation.endPage135-
dc.identifier.bibliographicCitationEUROPEAN JOURNAL OF CANCER, Vol.57 : 127-135, 2016-
dc.date.modified2017-02-24-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.